Latest News

4th Quality & Innovation Meeting – Pancreatic Disorders

Another important date for the fight to Pancreas Disorders. Today, Oncologica will participate at the 4th “Quality & Innovation Meeting” focused on Pancreatic Disorders, that will take place in the Ospedale San Raffaele (Milan). Leading international experts in the medical community will discuss the most relevant innovations in Pancreatic Cancer, including aspects of precision oncology […]

Read More

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Background: In order to facilitate implementation of precision medicine in clinical management of cancer, there is a need to harmonise and standardise the reporting and interpretation of clinically relevant genomics data. Methods: The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to propose a […]

Read More

Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in Non-Small-Cell-Lung Cancer (NSCLC)

This year’s Nobel Prize in Physiology or Medicine for discoveries relating to the harnessing of the immune system in the treatment of cancer has highlighted the great benefits of this approach to therapy. Multiple immunotherapies targeting the immune checkpoint programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway are now approved for the treatment of patients […]

Read More

Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs

The impact of precision oncology on guiding treatment decisions of late-stage cancer patients was previously studied in a retrospective analysis. However, the overall survival and costs were not previously evaluated. We report the overall survival and healthcare costs associated with precision oncology in these patients with advanced cancer. Building on a matched cohort study of 44 patients with metastatic […]

Read More

Nobel prize for medicine goes to cancer therapy

Two scientists who discovered how to fight cancer using the body’s immune system have won the 2018 Nobel Prize for physiology or medicine. The work, by Professor James P Allison from the US and Professor Tasuku Honjo from Japan, has led to treatments for advanced, deadly skin cancer. Immune checkpoint therapy has revolutionised cancer treatment, said […]

Read More

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

Oncologica contributes to a seminal study by Paul Scorer, in partnership with colleagues in the IMED Biotech Unit at AstraZeneca, who have investigated the consistency of tumour and immune cell programmed cell death ligand-1 expression, within and between tumour blocks, using the VENTANA SP263 assay. Several anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 […]

Read More

DNA ‘barcode’ delivering personalised breast cancer care

Scientists in Cambridge say advances in genetics are set to transform the treatment of breast cancer, making it more personalised to each patient. All women there diagnosed with breast cancer have their entire genetic code mapped. Doctors say it is helping them chose the right treatment and predict whether patients are likely to experience side effects. It […]

Read More

OncoCheckpoint: Companion DX for Cdc7 inhibitors

Oncologica has established the first comprehensive predictive test for Cdc7 inhibitors using its state of the art Next Generation Sequencing platform validated for the delivery of Oncologica’s precision oncology clinical services. Our newly developed Cdc7 companion Dx “OncoCheckpoint” analyses the major signalling components of the DNA replication origin activation checkpoint for all activating/inactivating genetic aberrations that […]

Read More

AML and chemotherapy. A study recently co-authored by Oncologica

The ability to assess which patients with acute myeloid leukemia (AML) will derive benefit from chemotherapy is a challenge using current technologies. Oncologica has recently co-authored a study in which we show that analysis of the proliferative state of leukemic tumour cells exploiting the evolutionary conserved proteins that replicate a cell’s DNA can be used […]

Read More

THE ONCOFOCUS TEST

Here at Happy Magazine we try to focus on all things positive for the cancer journey. This can be anything from a tasty recipe to a motivational video or a great new product which we think might be helpful. We try to steer clear of any heavy medical information as we feel that there is […]

Read More

Revolutionary test can tailor the best therapy for cancer patients

A revolutionary new test, which takes the “guesswork” out of deciding what treatment will be most effective for a cancer patient, has been launched in Ireland. Dr David Fennelly, oncologist at St Vincent’s Hospital in Dublin, said the Oncofocus test has great potential to improve the survival of cancer patients. This will include not just […]

Read More

Oncofocus Cancer Test and targeted therapies. The Revolution in cancer treatment has begun.

Chemotherapy is no longer the only option against cancer, there are now more than 600 targeted therapies available to treat solid tumours. Targeted therapies are the cornerstone of personalized medicine, a form of medicine that uses information about a person’s DNA profile to treat cancer.  The Oncofocus test can identify new treatment options in 85% of […]

Read More